Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

E-Newsletter

  • Subscribe to our e-Newsletter to receive email updates:

  • Related Articles

    Most Recent

    Archives

    Join Us

    News: Igor Puzanov

    Melanoma Drug Risks Studied

    Friday, March 23rd, 2012

    Melanoma patients who are treated with new oral drugs inhibiting the BRAF gene are at increased risk for developing secondary skin cancers. A new study co-authored by Vanderbilt-Ingram Cancer Center investigators and researchers from 12 other cancer centers discovered clues that may explain what is triggering these secondary cancers. VICC’s Igor Puzanov, M.D., assistant professor […]

    Symposium set for Melanoma Survivors

    Friday, March 2nd, 2012

    Vanderbilt-Ingram Cancer Center melanoma experts will hold a patient education symposium for melanoma survivors and caregivers on Saturday, March 10, from 9:30 a.m. to 2:30 p.m. in the Preston Research Building, Room 898J. The free symposium, co-sponsored by the Melanoma Research Foundation, is open to all melanoma patients, no matter where they received their treatment. […]

    New Melanoma Therapy Shows Promise

    Friday, November 12th, 2010

    A clinical trial of a new experimental therapy for metastatic melanoma being tested at Vanderbilt and several other medical centers has shown positive results, including tumor shrinkage in the majority of patients. The results support previously reported positive data for the drug, known as PLX4032 (RG7204), in a much larger patient population where all responses […]

    New Melanoma Drug Creates Excitement

    Thursday, September 2nd, 2010

    A new drug used to treat advanced melanoma patients with a specific genetic mutation in their tumors demonstrated significant tumor shrinkage in the majority of patients during a clinical trials.